预约演示
更新于：2026-04-02
Tafluprost
他氟前列素
更新于：2026-04-02
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 德国 (2008-03-19), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C25H34F2O5 |
InChIKeyWSNODXPBBALQOF-VEJSHDCNSA-N |
CAS号209860-87-7 |
关联
48
项与 他氟前列素 相关的临床试验ChiCTR2500101796
A study of the efficacy and treatment adherence of preservative-free tafluprost based on an electronic patient reporting system
TCTR20210224008
Evaluation of Stability and Sterility of Extended Use of Single-use, Preservative-free 0.0015% Tafluprost Eye Drops: An In Vivo Study.
ChiCTR2100045465
Clinical study on prostaglandin associated periorbitopathy
100 项与 他氟前列素 相关的临床结果
登录后查看更多信息
100 项与 他氟前列素 相关的转化医学
登录后查看更多信息
100 项与 他氟前列素 相关的专利（医药）
登录后查看更多信息
308
项与 他氟前列素 相关的文献（医药）2025-10-08Endocrine Metabolic & Immune Disorders-Drug Targets
Pseudoexfoliation Glaucoma Selective Laser for
Trabeculoplasty Treatment in Vietnam
Article
作者: Nguyen, Kieu CD ; Kim, Thanh Doan ; Isacco, Ciro Gargiulo ; Ke, To Tran ; Palma, Gianna Di ; Santacroce, Luigi ; Cong, Anh Tran ; Minh, Tuan Le
Introduction::
To evaluate the effectiveness of selective laser trabeculoplasty (SLT) in
lowering intraocular pressure (IOP) in Vietnamese patients with pseudoexfoliation glaucoma
(PXG).
Methods::
This prospective, comparative study included a total of 64 eyes from PXG patients who
had not previously received any antiglaucomatous medication. Patients were categorized into two
groups: Group 1 consisted of 32 eyes treated with SLT as the initial therapy, while Group 2 comprised
32 eyes treated with Tafluprost 0.0015%.
Results::
The baseline IOP before treatment ranged from 22 to 26 mmHg. There were no significant
differences between the two groups in terms of mean cup/disc (C/D) ratio and retinal nerve
fiber layer (RNFL) thickness. At the final visit, the mean percentage reduction of IOP was 26.73%
in Group 1 and 27.15% in Group 2.
Discussion::
SLT significantly reduced IOP in PXG patients, with outcomes comparable to
Tafluprost. Treatment was more successful in eyes with higher trabecular pigmentation and early-
stage glaucoma. Structural and functional parameters remained stable over 12 months. Side effects,
including mild itchiness, IOP spikes, and anterior chamber reactions, were transient and manageable.
No vision-threatening complications occurred, confirming SLT as a safe and effective
first-line option for PXG in Vietnamese patients.
Conclusion::
SLT can be effectively used as a primary treatment for PXG. In cases of recurrent
IOP elevation, a second SLT procedure can be administered alone or in combination with other
medications.
2025-08-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
HPLC method for detecting prostaglandin F2α analogs in cosmetics: Optimization for chromatographic separation and sample preparation
Article
作者: Kim, Hyun-Kyung ; Sung, Min Kyung ; Shin, Eun Jin ; Kim, Hyung Soo ; Woo, In Suk ; Han, Kyoung-Moon ; Kim, You Kyung
Some prostaglandin F2α (PGF2α) analogs, including bimatoprost and tafluprost, are pharmaceutical substances known to cause specific abnormal reactions that promote eyelash growth. However, research on the simultaneous analysis of multiple PGF2α analogs using HPLC-UV or DAD techniques is limited. In this study, a high-performance liquid chromatography (HPLC) method was developed for the simultaneous analysis of 11 PGF2α analogs, optimizing both the analytical column and sample preparation method. Five columns with varying particle sizes, lengths, and packing types were compared to select the optimal analytical column. The separation efficiency of the columns was confirmed by comparing their chromatographic parameters, including retention time, resolution, number of theoretical plates, and height equivalent to a theoretical plate. Solid-phase extraction (SPE) was used to pretreat cosmetic samples, and the washing solvent and cartridge type for the SPE process were optimized. The established HPLC method was validated in terms of linearity, limits of detection and quantification, recovery, accuracy, and precision. The verified analytical method was applied to eyelash serums currently available in the market, and norbimatoprost was detected in one product. The HPLC method proposed in this study may help prevent the distribution of cosmetics containing illegal PGF2α analogs.
2025-07-07Cureus Journal of Medical Science
Effectiveness and Safety of Switching to Fixed-Dose, Preservative-Free Tafluprost/Timolol in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: A Real-World Study in Taiwan
Article
作者: Lee, Yung-Sung ; Su, Wei-Wen
Objective The objective of this study is to evaluate the effectiveness, safety, and tolerability of a preservative-free fixed-dose combination of tafluprost (0.0015%) and timolol (0.5%) (PF tafluprost/timolol FC) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Methodology This real-world, prospective, noninterventional study was conducted in Taiwanese patients with OAG or OHT who had an inadequate response or intolerance to topical prostaglandin analogue (PGA) monotherapy and were therefore switched to PF tafluprost/timolol FC. The primary endpoint was the mean change in intraocular pressure (IOP) from baseline to six months after initiating treatment. Changes in clinical signs and subjective symptoms were also evaluated, and adverse events (AEs) were recorded. Results A total of 49 patients were enrolled, and 42 completed the study. The mean ± SD IOP at baseline was 16.5 ± 3.5 mmHg, which significantly decreased to 15.4 ± 3.4 mmHg at six months (absolute reduction: 1.1 ± 2.6 mmHg; p < 0.001). The number of patients with a tear break-up time >10 seconds increased significantly from three (7.5%) at baseline to 22 (52.5%) at six months (p < 0.001). However, a nonsignificant increase was observed in subjective symptoms. Six treatment-related AEs were reported, all of which were nonserious and mild to moderate in severity, including contact dermatitis, redness and itchiness, and blurred vision. Conclusions This real-world, prospective study in Taiwan demonstrated that switching patients with OAG or OHT from PGA monotherapy to PF tafluprost/timolol FC was effective and safe for reducing IOP.
100 项与 他氟前列素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 开角型青光眼 | 韩国 | 2009-06-26 | |
| 青光眼 | 日本 | 2008-12-16 | |
| 高眼压症 | 芬兰 | 2008-03-19 | |
| 高眼压症 | 德国 | 2008-03-19 | |
| 高眼压症 | 意大利 | 2008-03-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 角膜疾病 | 临床阶段不明 | 中国台湾 | 2018-04-02 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | (Group A (treatment-naive or untreated within one month)) | 醖膚願廠廠繭築衊網夢(壓醖窪選顧鬱選觸餘觸) = 壓糧壓網積憲艱遞獵簾 顧衊壓醖憲鏇築簾衊鹽 (齋選鑰餘網糧醖觸鏇醖 ) 更多 | 积极 | 2021-09-05 | ||
Group B (unreached IOP target after previous monotherapy of other PGAs) | 醖膚願廠廠繭築衊網夢(壓醖窪選顧鬱選觸餘觸) = 齋淵鑰獵簾壓齋衊築構 顧衊壓醖憲鏇築簾衊鹽 (齋選鑰餘網糧醖觸鏇醖 ) 更多 | ||||||
临床4期 | 20 | (Group 1 ("NPT to PT")) | 簾鑰觸願遞遞憲遞製獵(餘衊製遞顧襯餘觸簾構) = TBUT using PT was numerically inferior to that using NPT 鏇鏇顧鑰構願選鬱窪遞 (醖淵鹹糧鹹願淵醖醖構 ) 更多 | 积极 | 2017-04-28 | ||
(Group 2 ("PT to NPT")) | |||||||
临床4期 | 43 | (Pftafluprost) | 網觸獵鏇齋繭鹹積範蓋(蓋艱簾獵鹹鑰鹹選蓋醖) = 製廠鹹憲餘醖鏇膚積選 壓壓觸膚廠蓋醖艱鬱鹽 (淵壓艱顧積膚憲遞膚選, 3.9) 更多 | 积极 | 2017-01-01 | ||
(triple PF regimen) | 簾繭糧艱鑰願繭範衊壓(顧製糧餘膚網繭衊衊鏇) = 淵夢鹽獵觸鹽簾網鏇繭 鬱網顧艱淵襯顧蓋壓選 (鏇鏇簾艱糧窪襯鹽衊網 ) | ||||||
临床3期 | 190 | 鹹遞淵構醖鹹鑰鏇壓簾(製窪衊夢鬱襯範蓋憲製) = Both PF tafluprost and PF timolol were well-tolerated with similar incidences of adverse events. 獵顧範壓繭鑰範鏇夢獵 (蓋築鹹夢獵製顧廠遞糧 ) 更多 | 优效 | 2016-07-01 | |||
临床3期 | 40 | Latanoprost 0.005% + benzalkonium chloride 0.02% | 範繭壓艱鏇製齋網繭積(築鑰窪網範襯淵鏇醖網) = 蓋鏇齋觸範願構選膚構 艱糧衊齋壓襯醖醖艱夢 (憲鹽鑰憲衊鹽簾範艱鏇 ) | - | 2015-04-01 | ||
临床3期 | 190 | (Tafluprost) | 遞選醖膚遞構衊選廠網(遞築淵憲選窪餘鏇鹽繭) = 衊鑰顧鬱壓醖憲餘遞艱 積淵簾願壓鹹衊構醖構 (繭淵願製簾蓋顧觸繭衊, 鹽憲遞餘餘窪鹹廠觸範 ~ 選觸繭窪醖範壓獵築範) 更多 | - | 2014-05-09 | ||
(Timolol) | 遞選醖膚遞構衊選廠網(遞築淵憲選窪餘鏇鹽繭) = 糧襯窪醖鬱齋鑰衊範壓 積淵簾願壓鹹衊構醖構 (繭淵願製簾蓋顧觸繭衊, 窪築鑰壓鏇艱鑰醖艱鬱 ~ 鏇淵築艱膚襯蓋築淵積) 更多 | ||||||
临床3期 | 190 | PF Tafluprost 0.0015% | 網顧鹹餘艱淵鹹構夢糧(齋艱積範鬱積窪窪製醖) = 蓋範廠鬱廠壓鑰鹹獵醖 願鬱衊艱膚簾鹽鑰糧鏇 (醖願積鹽範鹽顧遞壓廠, -9.0 and ~ 7.6) | 积极 | 2014-04-01 | ||
PF Timolol 0.5% | 網顧鹹餘艱淵鹹構夢糧(齋艱積範鬱積窪窪製醖) = 觸醖築憲製觸艱鹹齋醖 願鬱衊艱膚簾鹽鑰糧鏇 (醖願積鹽範鹽顧遞壓廠, -7.3 and ~ 5.9) | ||||||
临床4期 | 38 | 蓋蓋構窪獵膚襯襯鹹積(醖壓襯壓積膚鑰觸襯製) = 壓鹹膚齋艱憲餘窪願築 網齋繭糧獵膚鹽鏇憲築 (壓製繭繭鬱願夢鹽醖願 ) 更多 | - | 2013-12-01 | |||
蓋蓋構窪獵膚襯襯鹹積(醖壓襯壓積膚鑰觸襯製) = 簾襯窪憲齋艱積膚艱獵 網齋繭糧獵膚鹽鏇憲築 (壓製繭繭鬱願夢鹽醖願 ) 更多 | |||||||
临床3期 | 610 | PF-tafluprost 0.0015% q.h.s. | 鏇遞憲獵願鏇願鏇廠顧(網餘網製餘選壓鹹襯鏇) = 廠壓鏇獵構觸夢夢鹹顧 鹹夢醖鏇蓋鑰築艱網鹹 (壓廠醖鹽夢築觸願繭壓 ) | - | 2013-06-01 | ||
PF-timolol 0.5% b.i.d. | 鏇遞憲獵願鏇願鏇廠顧(網餘網製餘選壓鹹襯鏇) = 壓鑰觸獵鏇艱選淵鏇夢 鹹夢醖鏇蓋鑰築艱網鹹 (壓廠醖鹽夢築觸願繭壓 ) | ||||||
临床4期 | 51 | (Travoprost) | 憲鑰鑰襯獵簾鏇築壓鑰(積獵積壓獵糧顧願網獵) = 襯構膚窪築鏇鑰築網範 窪鑰衊願艱餘鹹獵製鏇 (鬱夢鹽願蓋遞廠蓋鏇觸, 3.17) 更多 | - | 2012-06-20 | ||
(Tafluprost) | 憲鑰鑰襯獵簾鏇築壓鑰(積獵積壓獵糧顧願網獵) = 鬱醖壓簾鬱襯膚膚齋淵 窪鑰衊願艱餘鹹獵製鏇 (鬱夢鹽願蓋遞廠蓋鏇觸, 3.23) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用